Dr. Roffler, Steve R. 's publons link picture

羅傅倫博士

特聘研究員
Division Chief
  • 02-2652-3079 (Lab) (Room No: N233)
  • 02-2782-9142 (Fax)

Specialty:
  1. Antibody Engineering
  2. Directed Molecular Evolution
  3. Prodrugs

Education and Positions:
  • Ph.D. University of California, Berkeley


1. 抗體工程:建構雙特異性抗體抗體,用以遞送奈米藥物至腫瘤,改善癌症治療的選擇性與療效。

2. 奈米醫藥:正在研發新穎的技術,將疏水性藥物穩定包覆於奈米微脂體。

3. 定向分子演化:本實驗室已研發出有力的篩選方法,分選出定向演化後的優化人類酵素。我們以此技術提高蛋白質的性能,應用於治療遺傳疾病,與抗體-酵素前驅藥物療法。此外,本實驗室亦發展於抗體融合瘤細胞中,快速演化高親和力抗體的技術。

4. 前驅藥物療法:發展在腫瘤微環境內能夠優先被活化的前驅藥物,瞭解其機制以及改善活化的條件。

5. 聚乙二醇抗體:本實驗室研發聚乙二醇抗體,用以檢測人類血液檢體中聚乙二醇修飾藥物含量。我們亦延伸相關研究,探討人體中已存在,或被誘發產生的聚乙二醇抗體,是否會影響聚乙二醇修飾醫藥的療效。

Our Team
Team photo

  1. Lin YC, Chen BM, Tran TTM, Chang TC, Al-Qaisi TS, Roffler SR* Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture. Journal of controlled release : official journal of the Controlled Release Society 354, 354-367 (2023-01) [JCR] [WOS]
  2. Bavli Y, Chen BM, Gross G, Hershko A, Turjeman K, (Roffler S*), Barenholz Y* Anti-PEG antibodies before and after a first dose of Comirnaty(R) (mRNA-LNP-based SARS-CoV-2 vaccine). Journal of controlled release : official journal of the Controlled Release Society 354, 316-322 (2023) [JCR] [WOS]
  3. Burnouf PA, (Roffler SR), Wu CC, Su YC Glucuronides: From biological waste to bio-nanomedical applications. Journal of controlled release : official journal of the Controlled Release Society 349, 765-782 (2022-09) [JCR] [WOS]
  4. Sahoo BK, Lin YC, Tu CF, Lin CC, Liao WJ, Li FA, Li LH, Mou KY, (Roffler SR), Wang SP, Yeh CT, Yao CY, Hou HA, Chou WC, Tien HF, Yang RB* Signal peptide-CUB-EGF-like repeat-containing protein 1-promoted FLT3 signaling is critical for the initiation and maintenance of MLL-rearranged acute leukemia. Haematologica 10.3324/haematol.2022.281151, x (2022-08) [JCR] [WOS]
  5. Nguyen MT, Shih YC, Lin MH, (Roffler SR), Hsiao CY, Cheng TL, Lin WW, Lin EC, Jong YJ, Chang CY, Su YC Structural determination of an antibody that specifically recognizes polyethylene glycol with a terminal methoxy group. Communications chemistry 5(1), 88 (2022-08) [JCR] [WOS]
  6. Lin HJ, Liang TL, Chang YY, Liu DZ, Fan JY, (Roffler SR), Lin SY Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment. Pharmaceutics 14(6), 10.3390/pharmaceutic (2022-07) [JCR] [WOS]
  7. Kim J, Li C, Wang H, Kaviraj S, Singh S, Savergave L, Raghuwanshi A, Gil S, Germond A, Baldessari A, Chen B, (Roffler S), Fender P, Drescher C, Carter D, Lieber A Translational development of a tumor junction opening technology. Scientific reports 12(1), 7753 (2022-05) [JCR] [WOS]
  8. Cheng WJ, Chuang KH, Lo YJ, Chen M, Chen YJ, (Roffler SR), Ho HO, Lin SY, Sheu MT Bispecific T-cell engagers non-covalently decorated drug-loaded PEGylated nanocarriers for cancer immunochemotherapy. Journal of controlled release : official journal of the Controlled Release Society 344, 235-248 (2022-04) [JCR] [WOS]
  9. Wang H, Li C, Obadan AO, Frizzell H, Hsiang TY, Gil S, Germond A, Fountain C, Baldessari A, Roffler S, Kiem HP, Fuller DH, Lieber A In Vivo Hematopoietic Stem Cell Gene Therapy for SARS-CoV2 Infection Using a Decoy Receptor. Human gene therapy 33(7-8), 389-403 (2022-04) [JCR] [WOS]
  10. Cheng KW, Tseng CH, Chen IJ, Huang BC, Liu HJ, Ho KW, Lin WW, Chuang CH, Huang MY, Leu YL, (Roffler SR), Wang JY, Chen YL, Cheng TL Inhibition of gut microbial beta-glucuronidase effectively prevents carcinogen-induced microbial dysbiosis and intestinal tumorigenesis. Pharmacological research 177, 106115 (2022-03) [JCR] [WOS]

- 博士後研究 -
member
曾羿涵
member
張恬菁
member
邱柏全
Burnouf, Pierre-Alain
白宸睿
- 研究助理 -
member
吳品逸
member
唐璽楊
member
林頌堯
member
張鐙元
Yang, Seymour
楊世弘
- 學生 -
Lin, Ronald
林奕辰
- 昔日夥伴 -
member
皮喬偉